Jaguar Health Implements Stockholder Rights Plan Amid Acquisition Interest

Jaguar Health, Inc. has announced a limited duration stockholder rights plan following an acquisition interest in the company. This strategy aims to provide stockholders with extended time to realize their investment's long-term value amid market dislocations affecting stock prices.

The company is focused on advancing trials for crofelemer, a plant-based drug, targeting rare diseases like short bowel syndrome with intestinal failure and microvillus inclusion disease. Initial proof-of-concept results are anticipated in Q2 2025.

Further, Jaguar plans meetings with the FDA regarding successful trial outcomes for breast cancer patients. This comes as the company balances stockholder protection with acquisition opportunities, ensuring board involvement in significant interest negotiations.